Precision Therapeutics Inc.'s move to go public by way of a reverse merger with a special-purpose acquisition firm gives a boost to marketing of its ChemoFx test, which uses a patient's live tumor cells to measure the likelihood of response to cancer drugs. (BioWorld Today) Read More
